# US 7,393,524 B2 · Baculovirus vectors comprising a capsid polypeptide fused to a GNRH polypeptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,393,524 B2
- Document ID: US7393524B2
- Status: Granted
- Kind: B2
- Application number: 10/486,698
- Filed: 2002-08-15
- Published: 2005-01-13
- Granted: 2008-07-01
- Earliest claimed: 2001-08-15
- Assignees: Procure Therapeutics Limited
- Inventors: Norman Maitland
- Web page: https://patentgrep.com/patent/US7393524B2

## CPC

- C12N 15/86: Viral vectors
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a genetically engineered baculovirus wherein said virus is engineered to target therapeutic agents to cells, typically cancer cells, for example prostate cancer cells.

## Claims

### Claim 1

A baculovirus wherein the baculovirus genome has been modified to comprise a first polynucleotide which encodes a prodrug activating polypeptide and a second polynucleotide that encodes a baculovirus capsid polypeptide fused to a gonadotropin releasing hormone (GnRH) peptide consisting of the amino acid sequence SEQ ID NO: 2 that binds the baculovirus to the cell surface of a prostate cancer cell.

### Claim 2 (depends on 1)

A baculovirus according to claim 1 wherein the expression of said first polynucleotide is controlled by a cancer specific promoter.

### Claim 3 (depends on 2)

A baculovirus according to claim 2 wherein said cancer specific promoter is a prostate cancer cell specific promoter.

### Claim 4 (depends on 1)

A baculovirus according to claim 1 wherein said prodrug-activating polypeptide is selected from the group consisting of cytosine deaminase, theymidine kinase, nitroreductase RdxA, Cytochrome P450 CYP1A2, Cytochrome P450 CyP2E1 and Cytochrome P450 CYP3A4.

### Claim 5 (depends on 1)

A baculovirus according to claim 1 wherein said baculovirus capsid polypeptide is gp64.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the baculovirus according to claim 1 and a pharmaceutically acceptable excipient.